Bank of America
ZVSA

Bank of America’s ZyVersa Therapeutics ZVSA Stock Holding History

Bank of America’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-132
Closed -$90 – 8734
2025
Q2 		$90 Buy
132
+21
+19% +$14 ﹤0.01% 7985
2025
Q1 		$70 Buy
111
+2
+2% +$2 ﹤0.01% 7902
2024
Q4 		$115 Buy
109
+101
+1,263% +$159 ﹤0.01% 7712
2024
Q3 		$19 Buy
8
+1
+14% +$3 ﹤0.01% 7980
2024
Q2 		$26 Buy
+7
New +$38 ﹤0.01% 7960
2023
Q4 		– Hold
0
– -$13 – 8265
2023
Q3 		– Hold
0
– – – 7609
2023
Q2 		– Hold
0
– – – 7506

Other funds holding ZVSA

GA
Guerra Advisors Miami, Florida $271M AUM 27.78% 1-Year Est. Return

Bank of America's ZVSA Position: Q3 2025 in Review

Bank of America sold out of ZyVersa Therapeutics (ZVSA) in Q3 2025, closing a stake of 132 shares — an estimated $90 sold.

Bank of America first reported a position in ZVSA in Q2 2024 and held it in 5 quarters. The position peaked at $115 in Q4 2024. 1 fund tracked by Wall St. Rank holds ZVSA as of Q3 2025.

  • Bank of America reported no remaining ZyVersa Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Bank of America sold 132 ZyVersa Therapeutics shares in Q3 2025, an estimated $90.
  • Bank of America first reported a position in ZyVersa Therapeutics in Q2 2024 and held it in 5 quarters.
  • Bank of America's ZyVersa Therapeutics position peaked at $115 in Q4 2024.
  • 1 fund tracked by Wall St. Rank held ZyVersa Therapeutics as of Q3 2025.

Based on Bank of America's 13F filing for Q3 2025, filed 14 Nov 2025.